Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial

Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2025-11-03T20:59:54.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    42 days ago
    Change Detected
    Summary
    Major update: adds a government funding/operating status notice and updates version to v3.2.0, replacing the previous v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T05:36:10.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    Added a new version label (v3.1.0) and removed several drug-safety related sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) indicating a shift in content scope.
    Difference
    0.3%
    Check dated 2025-09-29T03:06:41.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Updated the page version from v3.0.1 to v3.0.2; the 'Back to Top' control was removed.
    Difference
    0.2%
    Check dated 2025-09-14T19:18:37.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.2%
    Check dated 2025-09-07T15:40:10.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The web page has been updated to include new facility information, drug details, and a range of medical publications, while removing several location and disease-related terms.
    Difference
    6%
    Check dated 2025-08-31T11:55:50.000Z thumbnail image

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.